Hostname: page-component-7c8c6479df-7qhmt Total loading time: 0 Render date: 2024-03-29T06:41:00.427Z Has data issue: false hasContentIssue false

A case of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) reinfection within ninety days of primary infection in a healthcare worker

Published online by Cambridge University Press:  22 February 2022

Mindy M. Sampson*
Affiliation:
Division of Infection Diseases, Department of Medicine, Atrium Health, Charlotte, North Carolina
Kimberly D. Reeves
Affiliation:
Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina
Christopher M. Polk
Affiliation:
Division of Infection Diseases, Department of Medicine, Atrium Health, Charlotte, North Carolina
Gregory A. Hawkins
Affiliation:
Department of Biochemistry, Wake Forest School of Medicine, Winston-Salem, North Carolina
Catherine L. Passaretti
Affiliation:
Division of Infection Diseases, Department of Medicine, Atrium Health, Charlotte, North Carolina
*
Author for correspondence: Mindy M. Sampson, E-mail: mindy.sampson@atriumhealth.org
Rights & Permissions [Opens in a new window]

Abstract

Type
Letter to the Editor
Copyright
© The Author(s), 2022. Published by Cambridge University Press on behalf of The Society for Healthcare Epidemiology of America

To the Editor—Case definitions and prior literature typically describe reinfections with severe acute respiratory coronavirus virus 2 (SARS-CoV-2) in situations when someone becomes infected >90 days from their prior infection. 1 Healthcare workers (HCWs) may be particularly susceptible to reinfection. Reference Adrielle Dos Santos, Filho and Silva2 With the emergence of the o (omicron) variant of SARS-CoV-2, an increased risk of reinfection has been described. Reference Pulliam, van Schalkwyk and Govender3 Here, we describe a case of reinfection that occurred only 2 weeks after the primary infection.

A 38-year-old female HCW developed a primary infection with SARS-CoV-2 in November 2021. She had no comorbidities or immunocompromising conditions. She was not vaccinated for SARS-CoV-2. Symptoms at that time consisted of fever, myalgias, headache, fatigue, congestion, and cough. A polymerase chain reaction (PCR) analysis of a nasopharyngeal (NP) swab sample collected 4 days after symptom presentation resulted in cycle threshold (Ct) values of 23.2 and 23.6, respectively, for the ORF1 and E genes on the Roche cobas platform (Roche Diagnostics, Basel, Switzerland). Subsequent analysis of the NP swab sample identified the δ (delta) variant (sublineage AY.3) as the causal pathogen.

The patient had complete resolution of symptoms. She received 1 dose of dexamethasone during her primary infection but otherwise received no treatment. Then, 7 weeks after her primary diagnosis, she developed fever, sore throat, fatigue, congestion, and cough. An NP swab sample was collected and tested 2 days after symptom onset, which was again positive for SARS-CoV-2. The Ct values were 20.92 and 20.95 for the ORF1 and E genes, respectively, on the Roche cobas platform. The sequence analysis of this second NP swab sample revealed the presence of the o variant (omicron sublineage BA.1), confirming a new infection of SARS-CoV-2.

This is a unique case demonstrating an early reinfection with SARS-CoV-2 occurring within 90 days of prior infection. Reinfection is likely to be more frequent with the o (omicron) lineage due to the escape of this variant from prior neutralizing SARS-CoV-2 antibodies. Reference Planas, Saunders and Maes4,Reference Cao, Wang and Jian5 Importantly, symptomatic individuals should be tested and evaluated for the possibility of reinfection, even within 90 days of their last infection. Understanding the dynamics of reinfections is particularly important as we update testing protocols and infection prevention policies during this surge of the omicron variant, and as we prepare for future emerging variants. This individual did have low Ct values, which would likely represent the presence of live virus; therefore, isolation would have been important to prevent continued spread. Reference Bullard, Dust and Funk6,Reference Jaafar, Aherfi and Wurtz7 This finding also highlights the importance of vaccination in our healthcare workers, given we now know that individuals who have completed their vaccine series and have received a booster are less likely to become infected with the o (omicron) variant. Reference Accorsi, Britton and Fleming-Dutra8 Cases like these also emphasize the importance of making genomic sequencing more widely available as we work to understand the virology and epidemiology of evolving variants.

Acknowledgments

We thank the research teams at Atrium Health and Wake Forest who support our sequencing efforts.

Financial support

The SARS-CoV-2 sequencing effort is supported by the CORonavirus VAriant SEQuencing (CORVASEQ) statewide surveillance effort. CORVASEQ is managed by the North Carolina Collaboratory at the University of North Carolina at Chapel Hill under a mandate from the North Carolina General Assembly and is funded by a $15 million grant through a partnership with the North Carolina Department of Health and Human Services and the US Centers for Disease Control and Prevention.

Conflicts of interest

All authors report no conflicts of interest relevant to this article.

References

Coronavirus disease 2019 (COVID-19) 2021 case definition. Centers for Disease Control and Prevention website. https://ndc.services.cdc.gov/case-definitions/coronavirus-disease-2019-2021/. Published 2021. Accessed January 30, 2022.Google Scholar
Adrielle Dos Santos, L, Filho, PGG, Silva, AMF, et al. Recurrent COVID-19 including evidence of reinfection and enhanced severity in thirty Brazilian healthcare workers. J Infect 2021;82:399406.Google ScholarPubMed
Pulliam, JRC, van Schalkwyk, C, Govender, N, et al. Increased risk of SARS-CoV-2 reinfection associated with emergence of the omicron variant in South Africa. medRxiv 2021. doi: 10.1101/2021.11.11.21266068.Google Scholar
Planas, D, Saunders, N, Maes, P, et al. Considerable escape of SARS-CoV-2 omicron to antibody neutralization. Nature 2021. doi: 10.1038/s41586-021-04389-z.Google ScholarPubMed
Cao, Y, Wang, J, Jian, F, et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature 2021. doi: 10.1038/s41586-021-04385-3.CrossRefGoogle ScholarPubMed
Bullard, J, Dust, K, Funk, D, et al. Predicting infectious SARS-CoV-2 from diagnostic samples. Clin Infect Dis 2020;71:26632666.CrossRefGoogle ScholarPubMed
Jaafar, R, Aherfi, S, Wurtz, N, et al. Correlation between 3790 qPCR positives samples and positive cell cultures including 1941 SARS-CoV-2 isolates. Clin Infect Dis 2020;72(11):e921.Google Scholar
Accorsi, EK, Britton, A, Fleming-Dutra, KE, et al. Association between 3 doses of mRNA COVID-19 vaccine and symptomatic infection caused by the SARS-CoV-2 omicron and delta variants. JAMA 2022;327:639651.CrossRefGoogle ScholarPubMed